for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Endologix, Inc.

ELGX.OQ

Latest Trade

3.45USD

Change

0.00(0.00%)

Volume

15,169

Today's Range

3.41

 - 

3.50

52 Week Range

3.23

 - 

17.80

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
3.45
Open
3.45
Volume
15,169
3M AVG Volume
4.80
Today's High
3.50
Today's Low
3.41
52 Week High
17.80
52 Week Low
3.23
Shares Out (MIL)
17.61
Market Cap (MIL)
61.12
Forward P/E
-1.28
Dividend (Yield %)
--

Next Event

Q3 2019 Endologix Inc Earnings Release

Latest Developments

More

Endologix Delivers Written Notice To Terminate Certain Equity Distribution Agreement Dated Aug 13 Between Co, Piper Jaffray

Endologix Announces Exclusive Distributor Agreement With Boston Scientific For The Chinese Market

Endologix Reports Q2 Loss Per Share $1.50

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Endologix, Inc.

Endologix, Inc. is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company's products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens. The EVAR products include the Endologix AFX Endovascular AAA System (AFX), the VELA Proximal Endograft (VELA) and the Endologix Powerlink with Intuitrak Delivery System (Intuitrak). The EVAS product is the Nellix EndoVascular Aneurysm Sealing System (Nellix EVAS System). It offers accessories to facilitate the optimal delivery of its EVAR products, including compatible guidewires, snares, and catheter introducer sheaths.

Industry

Medical Equipment & Supplies

Contact Info

2 Musick

+1.949.5984741

https://endologix.com/

Executive Leadership

Daniel T. Lemaitre

Chairman of the Board

John Onopchenko

Chief Executive Officer, Chief Operating Officer, Director

Vaseem Mahboob

Chief Financial Officer

Michael V. Chobotov

Chief Technology Officer

Jeremy Bragg Hayden

General Counsel, Corporate Secretary

Key Stats

2.89 mean rating - 9 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.2K

2017

0.2K

2018

0.2K

2019(E)

0.1K
EPS (USD)

2016

-7.800

2017

-4.700

2018

-7.100

2019(E)

-2.720
Price To Earnings (TTM)
--
Price To Sales (TTM)
0.43
Price To Book (MRQ)
0.84
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
228.96
LT Debt To Equity (MRQ)
228.96
Return on Investment (TTM)
-30.74
Return on Equity (TTM)
-25.91

Latest News

Latest News

BRIEF-Endologix Reports Q1 Loss Per Share $0.24

* Q1 EARNINGS PER SHARE VIEW $-0.17 -- THOMSON REUTERS I/B/E/S

BRIEF-Endologix Appoints John Onopchenko As Chief Executive Officer

* ENDOLOGIX APPOINTS JOHN ONOPCHENKO AS CHIEF EXECUTIVE OFFICER

BRIEF-Endologix Reports Positive Results From Global Encore Analysis With Polymer Endovascular Aneurysm Repair

* ENDOLOGIX INC - POSITIVE RESULTS FROM GLOBAL ENCORE ANALYSIS WITH POLYMER ENDOVASCULAR ANEURYSM REPAIR USING OVATION ABDOMINAL STENT GRAFT SYSTEMS Source text for Eikon: Further company coverage:

BRIEF-Endologix Inc CEO John McDermott Steps Down

* JOHN MCDERMOTT STEPS DOWN AS CHIEF EXECUTIVE OFFICER OF ENDOLOGIX, INC.

BRIEF-Endologix Posts Q4 Loss Per Share $0.17

* ENDOLOGIX REPORTS FOURTH QUARTER AND FISCAL YEAR 2017 FINANCIAL RESULTS

BRIEF-Endologix Completes Patient Enrollment In The Elevate IDE Clinical Study

* ENDOLOGIX, INC. COMPLETES PATIENT ENROLLMENT IN THE ELEVATE IDE CLINICAL STUDY Source text for Eikon: Further company coverage:

BRIEF-Endologix- On Jan 5, Co Delivered Notice Of Termination To Deerfield Elgx Revolver As Agent Under Credit, Security Agreement Dated As Of April 3, 2017

* ENDOLOGIX- ON JAN 5, CO DELIVERED NOTICE OF TERMINATION TO DEERFIELD ELGX REVOLVER AS AGENT UNDER CREDIT, SECURITY AGREEMENT DATED AS OF APRIL 3, 2017

BRIEF-Endologix Q3 loss per share $0.17

* Q3 earnings per share view $-0.17 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

BRIEF-Endologix appoints John Onopchenko as chief operating officer

* Endologix appoints John Onopchenko as chief operating officer Source text for Eikon: Further company coverage:

BRIEF-Endologix says operations not materially affected by Santa Rosa fires

* Comments on impact of the Santa Rosa fires impact on co's facility

BRIEF-ENDOLOGIX GETS FDA NOD TO BEGIN CONFIRMATORY CLINICAL STUDY ON ITS NELLIX EVAS SYSTEM

* ENDOLOGIX RECEIVES IDE APPROVAL FOR THE EVAS2 CONFIRMATORY CLINICAL STUDY TO EVALUATE THE NELLIX® ENDOVASCULAR ANEURYSM SEALING SYSTEM

BRIEF-Endologix announces CE Mark approval for Nellix Endovascular Aneurysm Sealing System

* Endologix announces CE Mark approval for the Nellix Endovascular Aneurysm Sealing System with the refined indications for use

BRIEF-Endologix announces collaboration agreements with Japan Lifeline

* Endologix announces collaboration agreements with Japan Lifeline for the development and commercialization of thoracic endovascular systems in Japan

BRIEF-Endologix Q2 loss per share $0.20

* Q2 earnings per share view $-0.18 -- Thomson Reuters I/B/E/S

BRIEF-Partner Fund Management reports 6.4 pct passive stake in Endologix

* Partner fund management, l.p. Reports 6.4 percent passive stake in endologix inc as of may 22, 2017 - sec filing Source text - http://bit.ly/2qGuWLN Further company coverage:

BRIEF-Endologix provides an update on the Nellix EVAS System

* Endologix provides an update on the Nellix Endovascular Aneurysm Sealing System U.S. regulatory status

BRIEF-Endologix reports Q1 loss per share $0.26

* Q1 earnings per share view $-0.21 -- Thomson Reuters I/B/E/S

BRIEF-Endologix enters into $170 mln credit facility with Deerfield Management

* Endologix enters into $170 million credit facility with Deerfield Management

BRIEF-Endologix enrollS first patients in ELEVATE IDE clinical study

* Endologix Inc announces enrollment of first patients in elevate IDE clinical study

BRIEF-Brown Capital reports a 10.58 pct passive stake in Endologix Inc

* Brown Capital Management LLC reports a 10.58 percent passive stake in Endologix Inc as of Feb 28, 2017 Source text:(http://bit.ly/2miclCd) Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up